AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical reut.rs/44oAZVZ
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
reut.rs
July 14, 2026 at 6:35 AM
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical reut.rs/44oAZVZ
AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment. on.wsj.com/3R6KXbx
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment.
on.wsj.com
July 14, 2026 at 6:59 AM
AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment. on.wsj.com/3R6KXbx
FDA Grants Accelerated Approval to Sunvozertinib for EGFR Exon 20 Insertion Mutations in NSCLC
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Sunvozertinib #NSCLC #LungCancer
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Sunvozertinib #NSCLC #LungCancer
FDA Approves Sunvozertinib for EGFR Exon 20 NSCLC
Sunvozertinib, developed by Dizal Pharmaceuticals, receives FDA accelerated approval for metastatic NSCLC with EGFR exon 20 mutations.
oncodaily.com
July 25, 2025 at 9:38 PM
FDA Grants Accelerated Approval to Sunvozertinib for EGFR Exon 20 Insertion Mutations in NSCLC
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Sunvozertinib #NSCLC #LungCancer
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Sunvozertinib #NSCLC #LungCancer
Dizal to Unveil Significant NSCLC Breakthroughs at ASCO 2026 Conference#China#Shanghai#Dizal#Golidocitinib#ZEGFROVY
Dizal to Unveil Significant NSCLC Breakthroughs at ASCO 2026 Conference
Dizal will showcase exciting advancements in its NSCLC treatment portfolio at ASCO 2026 with two oral presentations and a poster session, highlighting their innovative therapies.
third-news.com
April 21, 2026 at 4:52 PM
Dizal to Unveil Significant NSCLC Breakthroughs at ASCO 2026 Conference#China#Shanghai#Dizal#Golidocitinib#ZEGFROVY
Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025#China#Shanghai#Dizal#Golidocitinib#SSE688192
Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025
Dizal Pharmaceuticals showcased new advancements in its hematology pipeline, presenting promising data on golidocitinib and birelentinib during ASH 2025.
third-news.com
December 9, 2025 at 10:13 AM
Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025#China#Shanghai#Dizal#Golidocitinib#SSE688192
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
reut.rs
July 14, 2026 at 6:25 AM
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference#China#Shanghai#Dizal#Golidocitinib#ZEGFROVY
Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference
At the 2025 World Conference on Lung Cancer, Dizal presented innovations in treating non-small cell lung cancer, showcasing promising results with ZEGFROVY and golidocitinib.
third-news.com
September 9, 2025 at 10:05 AM
Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference#China#Shanghai#Dizal#Golidocitinib#ZEGFROVY
Dizal Partners with AstraZeneca to Commercialize Zegfrovy for Lung Cancer Treatment#China#Shanghai#AstraZeneca#Dizal#ZEGFROVY
Dizal Partners with AstraZeneca to Commercialize Zegfrovy for Lung Cancer Treatment
Dizal has secured a global exclusive licensing deal with AstraZeneca for Zegfrovy, a new therapy aimed at treating lung cancer with EGFR mutations. This partnership could advance treatment options significantly.
third-news.com
July 14, 2026 at 6:12 AM
Dizal Partners with AstraZeneca to Commercialize Zegfrovy for Lung Cancer Treatment#China#Shanghai#AstraZeneca#Dizal#ZEGFROVY
AstraZeneca pays up to $1.5B or EGFR lung cancer drug Zegfrovy from its spinoff Dizal | #biotech #pharma #cancer #LungCancer
AstraZeneca pays up to $1.5B for EGFR lung cancer drug Zegfrovy from its spinoff Dizal
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is
www.fiercepharma.com
July 16, 2026 at 1:43 PM
AstraZeneca pays up to $1.5B or EGFR lung cancer drug Zegfrovy from its spinoff Dizal | #biotech #pharma #cancer #LungCancer
#AstraZeneca has continued its pipeline-boosting deal spree in #China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
AstraZeneca adds another Chinese asset, from Dizal
AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
buff.ly
July 14, 2026 at 11:30 AM
#AstraZeneca has continued its pipeline-boosting deal spree in #China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
Dizal's ZEGFROVY® Shines in Phase 3 Study Defeating Chemotherapy in Lung Cancer Treatment#China#Shanghai#Dizal#EGFR_Mutation#ZEGFROVY
Dizal's ZEGFROVY® Shines in Phase 3 Study Defeating Chemotherapy in Lung Cancer Treatment
Dizal announced groundbreaking results from the WU-KONG28 trial, showcasing ZEGFROVY®'s superiority over chemotherapy in treating lung cancer.
third-news.com
May 29, 2026 at 1:03 PM
Dizal's ZEGFROVY® Shines in Phase 3 Study Defeating Chemotherapy in Lung Cancer Treatment#China#Shanghai#Dizal#EGFR_Mutation#ZEGFROVY
Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment#Shanghai#NSCLC#Dizal#ZEGFROVY
Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment
Dizal has unveiled significant Phase 3 results for ZEGFROVY, showcasing enhanced survival rates in lung cancer patients with EGFR mutations.
third-news.com
March 21, 2026 at 11:35 AM
AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B
Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post…
Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post…
AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B
Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B appeared first on GEN - Genetic Engineering and Biotechnology News .
news-area.com
July 15, 2026 at 1:57 PM
AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B
Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post…
Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post…
IDF targeted Hamas's underground infrastructure in the Dizal Balakh area of Gaza, as Hamas attempted to repair it despite the ceasefire agreement. IDF forces continue operations to eliminate threats.
June 29, 2026 at 8:16 PM
IDF targeted Hamas's underground infrastructure in the Dizal Balakh area of Gaza, as Hamas attempted to repair it despite the ceasefire agreement. IDF forces continue operations to eliminate threats.
Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment#China#Shanghai#NSCLC#Dizal#ZEGFROVY®
Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment
Dizal's clinical findings for ZEGFROVY® reveal promising antitumor efficacy as a front-line therapy against advanced NSCLC with uncommon mutations.
third-news.com
March 27, 2026 at 12:46 PM
Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment#China#Shanghai#NSCLC#Dizal#ZEGFROVY®
Dizal's ZEGFROVY® Receives Priority Review for Lung Cancer Treatment in China#China#Shanghai#Dizal#Lung_Cancer#ZEGFROVY
Dizal's ZEGFROVY® Receives Priority Review for Lung Cancer Treatment in China
Dizal's ZEGFROVY® (sunvozertinib) has been accepted for Priority Review by China's NMPA for treating EGFR exon 20 insertion-mutated NSCLC patients.
third-news.com
May 27, 2026 at 10:48 AM
Dizal's ZEGFROVY® Receives Priority Review for Lung Cancer Treatment in China#China#Shanghai#Dizal#Lung_Cancer#ZEGFROVY
阿斯利康通过全球收购 Zegfrovy 进一步巩固了其肿瘤学管线，致力于推进癌症治疗创新。 www.ipharmacenter.com/post/astraze...
#新闻 #制药 #医疗 #收购 #中国 #突发新闻
#新闻 #制药 #医疗 #收购 #中国 #突发新闻
AstraZeneca Bolsters Oncology Pipeline with Global Acquisition of Zegfrovy
AstraZeneca has finalized an agreement to acquire global rights to Zegfrovy (sunvozertinib), a targeted, irreversible EGFR inhibitor developed by Dizal Pharmaceutical. This strategic expansion is desi...
www.ipharmacenter.com
July 14, 2026 at 4:21 PM
A AstraZeneca fortalece seu portfólio de oncologia com a aquisição global da Zegfrovy, avançando significativamente em sua linha de tratamentos oncológicos. www.ipharmacenter.com/post/astraze...
#notícias #farmacêutica #saúde #aquisição #china #breaking
#notícias #farmacêutica #saúde #aquisição #china #breaking
AstraZeneca Bolsters Oncology Pipeline with Global Acquisition of Zegfrovy
AstraZeneca has finalized an agreement to acquire global rights to Zegfrovy (sunvozertinib), a targeted, irreversible EGFR inhibitor developed by Dizal Pharmaceutical. This strategic expansion is desi...
www.ipharmacenter.com
July 14, 2026 at 4:22 PM
A AstraZeneca fortalece seu portfólio de oncologia com a aquisição global da Zegfrovy, avançando significativamente em sua linha de tratamentos oncológicos. www.ipharmacenter.com/post/astraze...
#notícias #farmacêutica #saúde #aquisição #china #breaking
#notícias #farmacêutica #saúde #aquisição #china #breaking
アストラゼネカがZegfrovyのグローバル買収を発表。オンコロジーパイプラインを強化し、がん治療の発展を目指します。 www.ipharmacenter.com/post/astraze...
#ニュース #製薬 #ヘルスケア #買収 #中国 #速報
#ニュース #製薬 #ヘルスケア #買収 #中国 #速報
AstraZeneca Bolsters Oncology Pipeline with Global Acquisition of Zegfrovy
AstraZeneca has finalized an agreement to acquire global rights to Zegfrovy (sunvozertinib), a targeted, irreversible EGFR inhibitor developed by Dizal Pharmaceutical. This strategic expansion is desi...
www.ipharmacenter.com
July 14, 2026 at 4:21 PM
All in a day’s reading, if you’re following innovation#AGI #AIagentcivilizations #Akeso #Ambarella #AMD #Anthropic #artificialintelligence #Astra #Azure #Biocytogen #Block2 #ChatGPT #Chinesepharma #Claude #CrowdStrike #Dizal #DualityBio #gemini #GenInnov #GitLab #Grok #HubSpot #Hutchmed #hyundai #ja
September 7, 2026 at 8:00 PM
All in a day’s reading, if you’re following innovation#AGI #AIagentcivilizations #Akeso #Ambarella #AMD #Anthropic #artificialintelligence #Astra #Azure #Biocytogen #Block2 #ChatGPT #Chinesepharma #Claude #CrowdStrike #Dizal #DualityBio #gemini #GenInnov #GitLab #Grok #HubSpot #Hutchmed #hyundai #ja
AstraZeneca completes $1.5bn Zegfrovy licence deal with Dizal
AstraZeneca completes $1.5bn Zegfrovy licence deal with Dizal
AstraZeneca has finalised an exclusive global licence for lung cancer drug Zegfrovy, paying Dizal Pharmaceutical $600m upfront with up to $900m in further milestones.
dlvr.it
September 1, 2026 at 6:54 AM
AstraZeneca completes $1.5bn Zegfrovy licence deal with Dizal
Dizal to Showcase New Data on ZEGFROVY® for Lung Cancer Treatment at WCLC 2026#South_Korea#Seoul#Dizal#Lung_Cancer#ZEGFROVY
Dizal to Showcase New Data on ZEGFROVY® for Lung Cancer Treatment at WCLC 2026
Dizal announces the presentation of clinical data on ZEGFROVY®, its EGFR inhibitor, for non-small cell lung cancer at WCLC 2026 in South Korea.
third-news.com
August 21, 2026 at 8:07 AM
Dizal to Showcase New Data on ZEGFROVY® for Lung Cancer Treatment at WCLC 2026#South_Korea#Seoul#Dizal#Lung_Cancer#ZEGFROVY